The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests. Using AI, scientists found that images ...

Laura Esserman, MD, MBA, entered the exam room to find a new patient, a woman in her fifties dangling her feet from the exam bench. The patient had recently been diagnosed with ductal carcinoma in ...

The White House on Monday released a detailed memo on President Donald Trump's previously undisclosed MRI exam, fueling new scrutiny over transparency even as his physician reported entirely normal ...

The White House released a statement from President Donald Trump's physician saying the MRI scan Trump received during his recent physical was "preventative" and the results were "perfectly normal." ...

President Donald Trump said Sunday he’ll release the results of an MRI scan he underwent last month, though he admitted he didn’t know which part of his body was scanned. The MRI was part of a wider ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Former Prime Minister David Cameron has shared the ‘terrifying’ moment he was told he had prostate cancer. Speaking to The Times, Mr Cameron recalled how his wife had urged him to take a prostate ...

DEAR DR. ROACH: I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...

Medicus Pharma is advancing Teverelix, a recently acquired, clinical stage asset, designed to address limitations of current hormone therapies for prostate cancer and benign prostatic hyperplasia (BPH ...